Anteris Price Target Raised to $18, Highlighting 148% Upside on Trial Progress
Barclays boosted its price target for Anteris Technologies to $18.00, implying 148.3% upside from the $7.25 stock price. The company is enrolling patients in its global PARADIGM pivotal trial across the US and Europe, backed by a $320 million capital raise and new board appointees.
1. Barclays Raises Price Target
Barclays raised its price target for Anteris Technologies to $18.00 from $17.00, indicating a 148.3% potential increase from the $7.25 share price and reflecting strong analyst confidence in the company’s growth trajectory.
2. PARADIGM Trial Advances
The global PARADIGM pivotal trial for the DurAVR transcatheter heart valve system has commenced patient enrollment in both the United States and Europe, marking a significant milestone in the device’s clinical validation process.
3. Successful $320 Million Capital Raise
Anteris Technologies secured $320 million in January 2026 to fund its ongoing PARADIGM trial and support the commercialization of the DurAVR THV system, providing robust financial resources for its development roadmap.
4. Board Strengthened with New Appointments
The company appointed Susan Knight and Stephen Denaro to its board of directors, adding healthcare, finance, and governance expertise to guide strategic decision-making and support commercialization efforts.